NRx Pharmaceuticals (NRXP) Q2 2024 earnings summary

Executive summary

• Achieved key inflection points: scientific progress with two NDAs (NRX-100 and NRX-101) planned for late 2024, business foundation for a ketamine clinic roll-up, and financial stabilization through new investment and debt elimination.

• HOPE Therapeutics developed as a subsidiary for a ketamine clinic network, with audit completed, spinout planned, and public listing targeted.

• Secured $16.3 million in new senior secured debt financing, settled Streeterville Capital litigation, and eliminated toxic debt at a discount.

• Leadership transition planned to bring in a CEO with commercial pharmaceutical experience as commercial operations are prepared for 2025.

• NRX-101 granted QIDP, Fast Track, and Priority Review for cUTI; partnership options under review.

Financial highlights

• Q2 2024 net loss reduced to $7.9M from $8.7M in Q2 2023; six-month net loss improved to $14.4M from $19.8M year-over-year.

• Research and development expenses for Q2 2024 decreased to $2.8M from $3.9M in Q2 2023; general and administrative expenses for Q2 2024 were $4.2M.

• Cash and cash equivalents stood at $1.9M as of June 30, 2024, with a working capital deficit of $18.8M and accumulated deficit of $267.6M.

• Operating cash outflow for H1 2024 was $6.2M, improved from $13.9M in the prior year.

• Financing activities in H1 2024 provided $3.5M in cash, primarily from equity offerings and private placements.

Outlook and guidance

• NDAs for NRX-100 and NRX-101 expected to be filed in late 2024, with anticipated FDA decisions and commercial launches in 2025.

• HOPE Therapeutics spinout and clinic acquisition program to be financed through non-dilutive mechanisms, with independent funding expected.

• Sufficient capital secured to fund operations and FDA submissions through year-end 2024, but substantial doubt remains about long-term viability.

• Ongoing operational efficiencies to extend cash runway and support revenue generation.

• Initial commercial focus on the US market, with international expansion under consideration.